BeOne Medicines Ltd. (ONC)
361.17
+1.20
(+0.33%)
USD |
NASDAQ |
Sep 25, 16:00
361.17
0.00 (0.00%)
After-Hours: 19:59
BeOne Medicines Research and Development Expense (Annual) : 2.079B for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 2.079B |
| December 31, 2024 | 1.855B |
| December 31, 2023 | 1.698B |
| December 31, 2022 | 1.577B |
| December 31, 2021 | 1.416B |
| December 31, 2020 | 1.264B |
| December 31, 2019 | 910.05M |
| Date | Value |
|---|---|
| December 31, 2018 | 670.00M |
| December 31, 2017 | 264.68M |
| December 31, 2016 | 96.12M |
| December 31, 2015 | 58.25M |
| December 31, 2014 | 21.86M |
| December 31, 2013 | 13.46M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Basilea Pharmaceutica AG | 127.51M |
| Santhera Pharmaceuticals Holding AG | 26.75M |
| AC Immune SA | 67.96M |
| CRISPR Therapeutics AG | 265.33M |
| Idorsia Ltd. | 121.54M |